演題速報 デイリーランキング
このサイトは医療関係者の方々を対象に作成しています。
必ずご利用規約に同意の上、ご利用ください。記事内容で取り上げた薬剤の効能・効果および用法・用量には、日本国内で承認されている内容と異なるものが、多分に含まれていますのでご注意ください。
6月2日 演題レポート
Abstract #2537
Pharmacogenetic study in metastatic colorectal cancer (CRC) patients receiving 3rd-line panitumumab-irinotecan. A GERCOR ancillary study.
Marie-Christine Etienne-Grimaldi, et al.
Abstract #LBA4000
A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3)
Tom Samuel Waddell, et al.
Abstract #LBA4001
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer
Emilio Bajetta, et al.
Abstract #4002
Randomized phase III study of irinotecan (IRI) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial
Shinya Ueda, et al.
Abstract #LBA4003
Phase II-III randomized trial of definitive chemoradiotherapy with FOLFOX or cisplatin and fluorouracil in esophageal cancer: Final results of the PRODIGE 5/ACCORD 17 trial
Thierry Conroy, et al.
Abstract #4005
Evaluation of MET pathway biomarkers in a phase II study of Rilotumumab or placebo in combination with Epirubicin/ Cisplatin/ Capecitabine in patients with locally advanced or metastatic gastric or esophagogastric junction cancer
Kelly S. Oliner, et al.
Abstract #4006
Tivantinib (ARQ 197) vs. placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT)
Lorenza Rimassa, et al.